Maria Sharapova's doping ban was reduced from two years to 15 months
today, meaning the Russiantennis star can come back in April and return
to Grand Slam play at the French Open.
The Court of Arbitration for Sport cut nine months off the suspension
imposed on Sharapova, who tested positive for meldonium at the
Australian Open in January.
Sharapova, a five-time Grand Slam champion and former No. 1-ranked
player, appealed to CAS in June seeking to overturn or reduce the
two-year suspension imposed by the International Tennis Federation.
The CAS panel found that Sharapova "bore some degree of fault" for the
positive test, saying a 15-month sanction was "appropriate."
The ban took effect on Jan. 26 and was originally due to run until Jan.
25, 2018. Now she will be eligible to return nearly a year earlier.
"I've gone from one of the toughest days of my career last March when I
learned about my suspension to now, one of my happiest days, as I found
out I can return to tennis in April," Sharapova said in a statement.
"In so many ways, I feel like something I love was taken away from me
and it will feel really good to have it back," she added. "Tennis is my
passion and I have missed it. I am counting the days until I can return
to the court."
Steve Simon, CEO of the WTA tour, welcomed the ruling.
"We are pleased that the process is now at completion and can look forward to seeing Maria back on court in 2017," he said.
An independent ITF panel had found that Sharapova did not intend to
cheat but that she bore "sole responsibility" and "very significant
fault" for the positive test.
The panel also said the case "inevitably led to the conclusion" that she
took the substance "for the purpose of enhancing her performance."
Sharapova acknowledged taking meldoni um before each match at the
Australian Open, where she lost in the quarterfinals to Serena Williams.
Sharapova said she was not aware that meldonium, also known as
mildronate, had been included on the World Anti-Doping Agency's list of
banned substances from Jan. 1, 2016.
The ITF said she also tested positive for meldonium in an out-of-competition control in Moscow on Feb. 2.
The 29-year-old Sharapova missed this year's French Open, Wimbledon and U.S. Open, as well as the Olympics in Rio de Janeiro.
Sharapova said she was first prescribed the Latvian-made drug, typically
used for heart conditions, by her family doctor for various medical
issues in 2006. She cited a bout of the flu, possible onset of diabetes
and a magnesium deficiency.
Meldonium increases blood flow, which improves exercise capacity by carrying more oxygen to the muscles.
More than 100 athletes, including many Russians and other eastern Europeans, tested positive for meldonium early in the year.
Some escaped with no sanctions because they argued successfully that
they stopped taking the drug before Jan. 1 and that traces had lingered
in their system. Sharapova, however, acknowledged that she used
meldonium after Jan. 1.